210 related articles for article (PubMed ID: 24815779)
1. The role of Rixubis™ in the treatment of hemophilia B.
Valentino LA
Immunotherapy; 2014; 6(4):381-94. PubMed ID: 24815779
[TBL] [Abstract][Full Text] [Related]
2. BAX326 (recombinant coagulation factor IX) for the treatment and prophylaxis of hemophilia B.
Windyga J; Abbuehl BE; Hafeman AE
Expert Rev Hematol; 2014 Jun; 7(3):333-42. PubMed ID: 24832133
[TBL] [Abstract][Full Text] [Related]
3. Clinical evaluation of recombinant factor IX.
White G; Shapiro A; Ragni M; Garzone P; Goodfellow J; Tubridy K; Courter S
Semin Hematol; 1998 Apr; 35(2 Suppl 2):33-8. PubMed ID: 9565165
[TBL] [Abstract][Full Text] [Related]
4. Haemophilia B: current pharmacotherapy and future directions.
Franchini M; Frattini F; Crestani S; Bonfanti C
Expert Opin Pharmacother; 2012 Oct; 13(14):2053-63. PubMed ID: 22946758
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of plasma-derived and recombinant factor IX - implications for prophylaxis and on-demand therapy.
Björkman S
Haemophilia; 2013 Nov; 19(6):808-13. PubMed ID: 23786333
[TBL] [Abstract][Full Text] [Related]
6. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates.
Roth DA; Kessler CM; Pasi KJ; Rup B; Courter SG; Tubridy KL;
Blood; 2001 Dec; 98(13):3600-6. PubMed ID: 11739163
[TBL] [Abstract][Full Text] [Related]
7. Safe switching from a pdFIX (Immunine®) to a rFIX (Bax326).
Solano Trujillo MH; Stasyshyn O; Rusen L; Serban M; Lamas JL; Perina FG; Urasinski T; Oh M; Knowlton WB; Valenta-Singer B; Pavlova BG; Abbuehl B
Haemophilia; 2014 Sep; 20(5):674-81. PubMed ID: 24720694
[TBL] [Abstract][Full Text] [Related]
8. In silico evaluation of limited blood sampling strategies for individualized recombinant factor IX prophylaxis in hemophilia B patients.
Preijers T; Hazendonk HCAM; Fijnvandraat K; Leebeek FWG; Cnossen MH; Mathôt RAA
J Thromb Haemost; 2017 Sep; 15(9):1737-1746. PubMed ID: 28688133
[TBL] [Abstract][Full Text] [Related]
9. [Successful management of neurosurgical procedures with continuous infusion of recombinant factor IX in a child with hemophilia B].
Yamamoto M; Nakadate H; Iguchi U; Masuda H; Sakai H; Ishiguro A
Rinsho Ketsueki; 2013 Mar; 54(3):300-4. PubMed ID: 23676647
[TBL] [Abstract][Full Text] [Related]
10. Recombinant factor IX: discrepancies between one-stage clotting and chromogenic assays.
Wilmot HV; Hogwood J; Gray E
Haemophilia; 2014 Nov; 20(6):891-7. PubMed ID: 24800651
[TBL] [Abstract][Full Text] [Related]
11. Current management of hemophilia B: recommendations, complications and emerging issues.
Franchini M
Expert Rev Hematol; 2014 Oct; 7(5):573-81. PubMed ID: 25112898
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of recombinant factor IX after intravenous and subcutaneous administration in dogs and cynomolgus monkeys.
McCarthy K; Stewart P; Sigman J; Read M; Keith JC; Brinkhous KM; Nichols TC; Schaub RG
Thromb Haemost; 2002 May; 87(5):824-30. PubMed ID: 12038784
[TBL] [Abstract][Full Text] [Related]
13. Nonacog gamma, a novel recombinant factor IX with low factor IXa content for treatment and prophylaxis of bleeding episodes.
Turecek PL; Abbühl B; Tangada SD; Chapman M; Gritsch H; Rottensteiner H; Schrenk G; Mitterer A; Dietrich B; Höllriegl W; Schiviz A; Horling F; Reipert BM; Muchitsch EM; Pavlova BG; Scheiflinger F
Expert Rev Clin Pharmacol; 2015 Mar; 8(2):163-77. PubMed ID: 25660348
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B.
Windyga J; Lissitchkov T; Stasyshyn O; Mamonov V; Rusen L; Lamas JL; Oh MS; Chapman M; Fritsch S; Pavlova BG; Wong WY; Abbuehl BE
Haemophilia; 2014 Jan; 20(1):15-24. PubMed ID: 23834666
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacodynamic properties of plasma-derived vs. recombinant factor IX in patients with hemophilia B: a prospective crossover study.
Alamelu J; Bevan D; Sorensen B; Rangarajan S
J Thromb Haemost; 2014 Dec; 12(12):2044-8. PubMed ID: 25315324
[TBL] [Abstract][Full Text] [Related]
16. Progress in the treatment of bleeding disorders.
Bergman GE
Thromb Res; 2011 Jan; 127 Suppl 1():S3-5. PubMed ID: 21035836
[TBL] [Abstract][Full Text] [Related]
17. Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs.
Nolte MW; Nichols TC; Mueller-Cohrs J; Merricks EP; Pragst I; Zollner S; Dickneite G
J Thromb Haemost; 2012 Aug; 10(8):1591-9. PubMed ID: 22726310
[TBL] [Abstract][Full Text] [Related]
18. Trenonacog alfa for prophylaxis, on-demand and perioperative management of hemophilia B.
Brennan Y; Curnow J; Favaloro EJ
Expert Opin Biol Ther; 2018 Jan; 18(1):95-100. PubMed ID: 29172774
[TBL] [Abstract][Full Text] [Related]
19. Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates.
Iorio A; Fischer K; Blanchette V; Rangarajan S; Young G; Morfini M;
Thromb Haemost; 2017 Jun; 117(6):1023-1030. PubMed ID: 28357444
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human factor IX: replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B.
Brinkhous KM; Sigman JL; Read MS; Stewart PF; McCarthy KP; Timony GA; Leppanen SD; Rup BJ; Keith JC; Garzone PD; Schaub RG
Blood; 1996 Oct; 88(7):2603-10. PubMed ID: 8839853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
